menu

Time Is Vision: The Critical Role of Early Diagnosis and Referral in Neovascular AMD and RVO

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Time Is Vision: The Critical Role of Early Diagnosis and Referral in Neovascular AMD and RVO

close
0.25 credits
15 minutes
Time Is Vision: The Critical Role of Early Diagnosis and Referral in Neovascular AMD and RVO
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, who are on the frontlines of eye care, diagnose and refer patients early in the disease process to ensure the best visual outcomes for patients? Join the discussion with Dr. Dunbar and Dr. Shechtman to find out more about how time is vision for these patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Diana L. Shechtman, OD, FAAO
    Optometrist
    Retina Macular Specialists of Miami
    Miami, FL 

    Consulting Fees: Allergan, Regeneron Pharmaceuticals, Carl Zeiss

    Faculty:
    Mark T. Dunbar, OD, FAAO
    Director of Optometric Services
    Bascom Palmer Eye Institute, University of Miami
    Miami, FL 

    Consulting Fees: Allergan, Genentech, Regeneron Pharmaceuticals, Carl Zeiss
    Commercial Interest Speaker Bureau: Allergan, Genentech, Regeneron Pharmaceuticals, Carl Zeiss
    Ownership Interest: Leo Lens Pharma

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
    • Mindy Nash, OD has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
    • Stephanie Wenick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify pathophysiologic features that can lead to choroidal neovascularization and macular edema in neovascular AMD and RVO
    • Define pathways to achieve more consistent assessment of eye health in patients with risk factors for neovascular AMD and RVO
  • Target Audience

    This activity is designed to meet the educational needs of general optometrists.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiativ

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, who are on the frontlines of eye care, diagnose and refer patients early in the disease process to ensure the best visual outcomes for patients? Join the discussion with Dr. Dunbar and Dr. Shechtman to find out more about how time is vision for these patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Diana L. Shechtman, OD, FAAO
    Optometrist
    Retina Macular Specialists of Miami
    Miami, FL 

    Consulting Fees: Allergan, Regeneron Pharmaceuticals, Carl Zeiss

    Faculty:
    Mark T. Dunbar, OD, FAAO
    Director of Optometric Services
    Bascom Palmer Eye Institute, University of Miami
    Miami, FL 

    Consulting Fees: Allergan, Genentech, Regeneron Pharmaceuticals, Carl Zeiss
    Commercial Interest Speaker Bureau: Allergan, Genentech, Regeneron Pharmaceuticals, Carl Zeiss
    Ownership Interest: Leo Lens Pharma

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
    • Mindy Nash, OD has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
    • Stephanie Wenick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify pathophysiologic features that can lead to choroidal neovascularization and macular edema in neovascular AMD and RVO
    • Define pathways to achieve more consistent assessment of eye health in patients with risk factors for neovascular AMD and RVO
  • Target Audience

    This activity is designed to meet the educational needs of general optometrists.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiativ

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 5/11/21